跳至主要内容
临床试验/NCT07233863
NCT07233863招募中不适用

Effectiveness of Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer

Dharmais National Cancer Center Hospital1 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2024年3月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
136
试验地点
1
主要终点
BCRL improvement rate

研究概览

简要总结

This study aims to evaluate the effectiveness of the Lymphovenous Bypass (LVB) procedure compared to physiotherapy alone as secondary prevention of lymphedema in breast cancer patients undergoing axillary lymph node dissection.

详细描述

In the intervention group, LVB was performed with intima-to-intima coaptation using the super microsurgery technique. The anastomosis was between the afferent lymphatic vessel and the recipient vein. The upper extremity lymphedema (UEL) index and indocyanine green (ICG) lymphography are utilized to evaluate the progression of lymphedema.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

盲法说明

Blinding is implemented in two conditions: the principal researcher (Bayu Brahma) will not know the patient's identity or medical history when assessing indocyanine green (ICG) lymphography results, and the patients will not see the type of treatment they received.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Breast cancer patients aged ≥ 18 years with an ECOG score > 1
  • •Breast cancer patients with post-axillary lymph node dissection diagnosed with stage 0 and I lymphedema.
  • •Those who have never undergone lymphedema physiotherapy.

排除标准

  • •Patients with dermal backflow before axillary lymph node dissection (ALND).
  • •Patients with breast cancer lymphedema who are unable to undergo a 24-month follow-up at Dharmais Cancer Hospital.
  • •Patients with iodine allergy, severe asthma, decreased kidney function, pregnancy, or breastfeeding.

研究组 & 干预措施

Lymphovenous bypass (LVB)

Experimental

Sixty-eight subjects will be needed per group. LVB was performed by creating an intima-to-intima anastomosis between the afferent lymphatic vessels and the recipient veins. After surgery, follow-up will be done every 6 months for 2 years. During follow-up, a comprehensive evaluation will be performed, including history and physical examinations, radiological and histopathological examinations, UEL index, ICG lymphography, and quality-of-life evaluation. Each subject will complete the Lymphedema Quality of Life Questionnaire.

干预措施: Lymphovenous bypass (LVB) (Procedure)

Physiotherapy

No Intervention

Sixty-eight subjects will be needed per group. Patients will receive physiotherapy from trained physiotherapists. The protocol includes manual lymphatic drainage (massage techniques), compression, skin care, and arm exercises. Follow-up will be done every 6 months for 2 years. During follow-up, a comprehensive evaluation will be performed, including history and physical examinations, radiological and histopathological examinations, UEL index, ICG lymphography, and quality-of-life evaluation. Each subject will complete the Lymphedema Quality of Life Questionnaire.

结局指标

主要结局

BCRL improvement rate

时间窗: 24 months

BCRL definition: Post-operation subject condition with the presence of minimum DB 2 with one or both symptoms (swelling, heaviness), and an increment of UEL index \>10% compared to pre-operation OR Post-operation subject condition with presence of ≥ DB 2 with minimum area 30% in one arm region in one of the arm lymphatic pathways (anterior or posterior), without presence of symptoms (swelling or heaviness), and increment of UEL index \>10% compared to pre-operation. International Society of Lymphology (ISL) stage 1 definition: An early stage of lymphedema is characterized by soft tissue swelling that may subside with limb elevation or overnight rest, without permanent structural changes. BCRL improvement : Improvement in ICG lymphography stage with or without clinical signs (UEL \<10% and or symptoms improvement)

次要结局

  • Quality of life in lymphedema(24 months)
  • Adverse event of lymphedema(24 months)

研究者

发起方
Dharmais National Cancer Center Hospital
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Bayu Brahma

MD, PhD

Dharmais National Cancer Center Hospital

研究点 (1)

Loading locations...

相似试验